

032204  
22783


US PTO

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

*(Only for new nonprovisional application  
under 37 CFR 1.53(b))*

**APPLICATION ELEMENTS**

*See MPEP chapter 600 concerning utility patent  
application contents.*

<b>CERTIFICATE UNDER 37 C.F.R. 1.10</b>		Docket No. IVD 919-4
Express Mail Label No.: EL676469634US		
Date of Deposit: <u>March 22, 2004</u>		
I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231		
 <b>Signature</b>		
<b>ADDRESS TO:</b> <i>Commissioner for Patents Box Patent Application Washington, DC 20231</i>		

1.  Fee Transmittal Form

*(Submit an original, and a duplicate for fee processing)*

2.  Specification *Total Pages* 172  
*(preferred arrangement set forth below)*

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Sequence Listing or a Table Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.  Drawing(s) *(35 USC 113)* *Total Sheets*       

4.  Oath or Declaration/  
Power of Attorney *Total Sheets* 3

- a.  Newly executed (original or copy)
- b.  Copy from a prior application *(37 CFR 1.63(d))*  
*(for continuation/divisional with Box 16 completed)*
- i.  **DELETION OF INVENTOR(S)**

Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 CFR 1.63(d)(2) and 1.33(b).

5.  Application Data Sheet *(See 37 CFR 1.76)*

6.  CD-Rom or CD-R, Large Table or Computer Program  
*(Appendix)*

7.  Nucleotide and/or Amino Acid Sequence Submission  
*(if applicable, all necessary)*

- a.  Computer Readable Form (CFR)
- b.  Paper copy (identical to computer copy)
- c.  Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

8.  Assignment Papers (cover sheet & document(s))

9.  37 CFR 3.73(b) Statement  Power of Attorney

10.  English Translation Document *(if applicable)*

11.  Information Disclosure  Copies of IDS  
Statement (IDS)/PTO-1449 Citations

12.  Preliminary Amendment

13.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*

14.  Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)

15.  Other: Citation of References

16. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:

Continuation  Divisional  Continuation-in-part (CIP) of prior application no: 09/954,862

Prior Application Information: Examiner: Charanjit Aulakh Group Art Unit: 1625

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label 27546 or  Correspondence address below

Paul E. Dupont  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Telephone No.: (610) 889-6338  
Facsimile No.: (610) 889-8799

Respectfully submitted,

  
Paul E. Dupont  
Reg. No. 27,438

22581  
10/805733  
U.S. PTO  
032204

Application of: Bichon et al.

Docket No.: IVD 919-4

Divisional of U.S. Application Serial No. 09/954,862

FOR: Novel Human NK<sub>3</sub> Receptor-Selective Antagonist Compounds, Method for Obtaining Them And Pharmaceutical Compositions Containing Them

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label No.: EL676469634US

Date of Deposit: March 22, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

  
Signature

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b)  
 Application of: Bichon et al.

Prior Application Serial No.: 09/954,862

Prior Filing Date: September 18, 2001

Group Art Unit: 1625

Examiner: Aulakh, Charanjit

For: Novel Human NK<sub>3</sub> Receptor-Selective  
 Antagonist Compounds, Method for Obtaining Them  
 And Pharmaceutical Compositions Containing Them

Mail Stop Patent Application  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

## FEE TRANSMITTAL FORM

The filing fee for the above-identified has been calculated as shown below:

<u>Claims as Filed</u>					
	Number Filed		Number Extra	Rate	Basic Fee
Total Claims	23	-20 =	3	X \$ 18.00 =	\$ 54.00
Independent Claims	1	- 3 =	0	X \$ 86.00 =	\$ 0.00
Multiple dependent claims(s), if any	2			\$290.00 =	\$ 290.00
Total Filing Fee:					\$1,114.00

Please charge the following fees to Deposit Account No. 19-0091.

Filing Fee of \$ 1,114.00  
 Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any overpayment, to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

This application is being filed by "Express Mail" as of the date of this letter pursuant to 37 CFR 1.10(b).

Date: 3/22/04

Address:

Patent Department  
 Sanofi-Synthelabo Inc.  
 9 Great Valley Parkway  
 Malvern, PA 19355  
 Tele: (610) 889-6338  
 Fax: (610) 889-8799

  
 Paul E. Dupont  
 Reg. No. 27,438